Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Neurol. 2013 Feb;33(1):13-25. doi: 10.1055/s-0033-1343792. Epub 2013 May 25.

The use of interferon Beta and glatiramer acetate in multiple sclerosis.

Author information

1
Department of Neurology, University of California, San Francisco, California 94143-0114, USA. douglas.goodin@ucsf.edu

Abstract

The modern era of the therapy for multiple sclerosis began in the 1990s with introduction of interferon beta and glatiramer acetate. Now 20 years since the introduction of these disease modifying therapies, several alternatives have become available. Although, in many cases, these new agents seem especially effective, there is little head-to-head trial data to actually compare the efficacy of the newer agents to that of the older. Moreover, there is no doubt that these older agents are both effective and very safe - something which has not always proven true about the newer therapies. Consequently, there will continue to be a place for these injectable treatments, even as we move into an era where physicians are confronted with many treatment possibilities.

PMID:
23709209
DOI:
10.1055/s-0033-1343792
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Support Center